Abstract
The current vaccine against TB, bacille Calmette-Guèrin (BCG) fails to protect against the most prevalent disease form, the pulmonary TB in adults. Thus, it is not a satisfactory vaccine.
Given that T cells are central to protection against TB, future vaccine design should focus on T-lymphocyte populations. Most vaccines do not prevent infection but instead disease, that if they allow establishment of the pathogen in the host but prevent its harmful effects.
The development of synthetic peptide-based immunogens is emerging as a possible approach in human vaccination in the future, as a replacement for conventional vaccines that use killed or attenuated whole microorganisms. The advantages of such synthetic vaccines (high potency, low adverse reactions, low cross-reactivity and high stability) are offset somewhat by the poorer inherent immunogenicity of these constructs. There is a greater need therefore to develop adjuvant/carrier systems to increase the immunogenicity of these newer vaccine candidates.
Keywords: Adjuvants, peptidic vaccine, proteomics, subunit approach, BCG, TB, tuberculosis.
Current Drug Targets
Title:Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Volume: 14 Issue: 9
Author(s): Adriano Mollica, Azzurra Stefanucci and Roberto Costante
Affiliation:
Keywords: Adjuvants, peptidic vaccine, proteomics, subunit approach, BCG, TB, tuberculosis.
Abstract: The current vaccine against TB, bacille Calmette-Guèrin (BCG) fails to protect against the most prevalent disease form, the pulmonary TB in adults. Thus, it is not a satisfactory vaccine.
Given that T cells are central to protection against TB, future vaccine design should focus on T-lymphocyte populations. Most vaccines do not prevent infection but instead disease, that if they allow establishment of the pathogen in the host but prevent its harmful effects.
The development of synthetic peptide-based immunogens is emerging as a possible approach in human vaccination in the future, as a replacement for conventional vaccines that use killed or attenuated whole microorganisms. The advantages of such synthetic vaccines (high potency, low adverse reactions, low cross-reactivity and high stability) are offset somewhat by the poorer inherent immunogenicity of these constructs. There is a greater need therefore to develop adjuvant/carrier systems to increase the immunogenicity of these newer vaccine candidates.
Export Options
About this article
Cite this article as:
Mollica Adriano, Stefanucci Azzurra and Costante Roberto, Strategies for Developing Tuberculosis Vaccines: Emerging Approaches, Current Drug Targets 2013; 14 (9) . https://dx.doi.org/10.2174/1389450111314090002
DOI https://dx.doi.org/10.2174/1389450111314090002 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Enoyl-Acyl Carrier Protein Reductase (INHA)</i>: A Remarkable Target to Exterminate Tuberculosis
Anti-Infective Agents Bedside Balance Testing in Elderly People
Current Aging Science Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis
Current Drug Targets Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology From Small to Powerful: The Fragments Universe and its “Chem-Appeal”
Current Medicinal Chemistry Drug Targets from Human Pathogenic Amoebas: Entamoeba histolytica,Acanthamoeba polyphaga and Naegleria fowleri
Infectious Disorders - Drug Targets Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design HIV-Tuberculous Meningitis Co-Infection: A Systematic Review and Meta-Analysis
Current Pharmaceutical Biotechnology Nitric Oxide: Friendly Rivalry in Tuberculosis
Current Signal Transduction Therapy A Case of Pulmonary Tuberculosis Mimicking as Diffuse Alveolar Hemorrhage: A Case Report
New Emirates Medical Journal Surfactant Therapy of Pulmonary Conditions Excluding those with Primary Surfactant Deficiency and Bronchoscopy as Delivery Method: An Overview of Russian Patents and Publications
Recent Patents on Drug Delivery & Formulation Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Interaction Between Two Residues in the Inter-Domain Interface of Escherichia coli Peptidase N Modulates Catalytic Activity
Protein & Peptide Letters Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research Recent Progress in Biological Activities of Indole and Indole Alkaloids
Mini-Reviews in Medicinal Chemistry Editorial [ The Reversal of Drug Resistance from Bacteria to Cancer Cells Part - I Guest Editor: Joseph Molnar ]
Current Drug Targets